Jude Bio
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Technology Sq Ste 8, Cambridge, Mass...Website
judo.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Jude Bio
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new RNA medicines for systemic and renal diseases. With the company's STRIKE (Selectively Targeting RNA Into KidnEy) platform, the company uses a proprietary approach that harnesses a natural, endogenous mechanism to target oligonucleotide medicines to the kidney. The company's initial drug programs are ligand-siRNA conjugate drugs designed for receptor-mediated uptake by specific kidney cell types, resulting in gene silencing of disease-modifying target genes for systemic diseases.Explore more
Jude Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Jude Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Jude Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Jude Bio had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Jude Bio
Funding: Get notified immidiatlly once Jude Bio has new funding data
Jude Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Jude Bio recently announced quarterly report
Check out if Jude Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Jude Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Jude Bio
Find 2 more new buyers
Company Profile Activity
Activity Insights
Jude Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Jude Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Jude Bio.
Jude Bio financials insights
Gather financial insights about Jude Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Angel/Seed
$100M
Jude Bio Tech Stack
A closer look at the technologies used by Jude Bio
Jude Bio News & Media
Judo Bio Presents Data Demonstrating Sustained, Kidney-Selective Gene Silencing Across Species
In vivo studies demonstrate robust and durable gene silencing across rodents and non-human primatesJudo Bio Presents Data Demonstrating Mechanism of Receptor-mediated Delivery of Oligonucleotides Resulting in Gene Silencing in the Kidney
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the presentation of preclinical data that demonstrate a mechanism of uptake and trafficking of ligand-siRNA conjugates using megalin receptors to achieve targeted gene knockdown in proximal tubule epithelial cells (PTEC) of the kidney. The data is being presented at Kidney Week 2024, the annual meeting of the American Society of Nephrology, taking pl
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Jude Bio
Sign Up For FreeTo access detailed company insights
Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new RNA medicines for systemic and renal diseases. With the company's STRIKE (Selectively Targeting RNA Into KidnEy) platform, the company uses a proprietary approach that harnesses a natural, endogenous mechanism to target oligonucleotide medicines to the... Read More
